USCAP Updates of the WHO Classification of Brain and Pituitary Tumors 2024

USCAP Updates of the WHO Classification of Brain and Pituitary Tumors 2024

Regular price€130,00
/
Tax included. Shipping calculated at checkout.

  • Free Shipping on orders over 45$
  • In stock, ready to ship
  • Inventory on the way

Original release date: June 20, 2024

Course Description
USCAP Updates of the WHO Classification of Brain and Pituitary Tumors 2024 Capitalizing on the advancement in the molecular diagnostics, the 2021 WHO classification of central nervous system (CNS) tumors recommended substantial changes in taxonomy, nomenclature and grading of CNS tumors. Furthermore, 22 new tumor types/subtypes were introduced and 13 revised terminologies for tumor types/subtypes were implemented. This case-based course will provide a framework for using the contemporary molecular and morphological diagnostic criteria in pediatric and adult brain tumors and pituitary gland neoplasms. Expert faculty will lead sessions to ensure pathologists become familiar with these major changes in diagnostic criteria and utilize them in their daily practice.

This course is a collaboration between the American Association of Neuropathologists and USCAP.

Target AudiencePracticing academic and community pathologists, and pathologists-in-training

Learning ObjectivesUpon completion of this educational activity, learners will be able to:
  • Apply the 2021 CNS WHO taxonomy, nomenclature, grading and classification of adult-type diffuse gliomas.
  • Integrate morphologic and molecular diagnostic techniques to diagnose pediatric-type diffuse low-/high-grade gliomas.
  • Explain the role of integrated molecular diagnosis and histological criteria in the classification of other CNS tumors including ependymal, dural-based, nerve sheath, and CNS embryonal tumors.
  • Summarize the newly described tumor type/subtypes in the 2021 CNS WHO.
  • Apply the 2022 WHO classification of pituitary neuroendocrine tumors (PitNETs) according to cell-lineage and cell type.
  • Discuss the non-neuroendocrine tumors of the sellar region.
  • List the most common nervous system tumors and associated clinical scenarios that should raise suspicion for genetic tumor syndromes.
Topics

Sellar Region Tumors 1 (Neuroendocrine) – Sylvia L. Asa, MD, PhD


Section: 1 Presentation 2 Documents

Diffuse Gliomas – Arie Perry, MD


Section: 1 Presentation 2 Documents

Sellar Region Tumors 2 (Non-Neuroendocrine) – Sylvia L. Asa, MD, PhD


Section: 1 Presentation 2 Documents

Meningiomas and Mesenchymal Tumors – Arie Perry, MD


Section: 1 Presentation 2 Documents

Ependymal and CNS Embryonal Neoplasms – Daniel Brat, MD, PhD


Section: 1 Presentation 2 Documents

Nerve Sheath and Melanocytic Tumors – Melike Pekmezci, MD


Section: 1 Presentation 2 Documents

Circumscribed Glial and Glioneuronal Tumors – Daniel Brat, MD, PhD


Section: 1 Presentation 2 Documents

Genetic Tumor Syndromes of the Nervous System – Melike Pekmezci, MD


Section: 1 Presentation 2 Documents

- Orders under 45$ will have a shipping charge of a flat rate of 15$.

-Orders over 45$ will have Free Shipping.

This site is protected by hCaptcha and the hCaptcha Privacy Policy and Terms of Service apply.

Testimonials

★★★★★


“I find the taste of Moringa tea to be very refreshing and it definitely gives me a feeling of ‘wellness’. I appreciate the ethics of the company. Am looking forward to trying the cream”

Elain
★★★★★


”I love knowing that everything is 100% chemical-free and tested in Canada. I also respect the sustainable farming approach that supports both Canada and Ethiopia.”

Alycia
★★★★★

Since I drink Moringa Tea I feel so much better. My mouth was always so dry but since I drink this tea I have so much saliva I drool.

I cannot believe how much it has helped me with my breathing. I love it. I even eat all the leaves - Thank you for introducing me to this herbal tea. I'm 85 years old.

Richard Dorge
Winnipeg, MB

Recently viewed